Global COVID Rapid Diagnostic Test Market Size and Share Analysis 2023-2028
According to the report’s scope, rapid diagnostic tests (RDTs), also referred to as rapid tests, are simple and quick tests used for diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
The COVID rapid diagnostic test market was valued at USD 18.7 billion in the base year and is projected to reach USD 7.5 billion, with a compound annual growth rate (CAGR) of -10.90% during the forecast period.
USD 18.7 billion in 2021
Type, End User, Region
|No. of Companies Mentioned||
The rising number of global COVID-19 cases and the presence of different variants have created a demand for early symptom detection. In January 2023, the World Health Organization (WHO) reported approximately 753 million confirmed cases of COVID-19 globally, up from over 645 million confirmed cases in December 2022. The highest number of new weekly cases in 2023 were reported in Japan (419,033), followed by China (158,687), South Korea (148,261), Germany (64,545), and Brazil (51,176). Additionally, in November 2021, the WHO identified the omicron variant of the SARS-CoV-2 coronavirus and classified it as a variant of concern. The recent surge in COVID-19 cases has been linked to highly transmissible variants, including a subvariant known as BA.2 or “stealth omicron,” particularly in regions with lax safety protocols.
Rapid diagnostic tests offer quick results and are user-friendly. During the pandemic, companies focused on developing COVID-19 rapid diagnostic products, which further contributed to market growth. For instance, in May 2022, BD launched a high-throughput molecular diagnostic combination test for SARS-CoV-2 and Influenza A/B on the BD SARS-CoV-2/Flu assay for the BD COR System. This automated multiplexed real-time RT-PCR test can detect and differentiate SARS-CoV-2, influenza A, and influenza B from a single nasal sample taken from patients displaying signs of respiratory viral infection.
Challenges such as product recalls due to quality control issues, stringent regulations and policies related to COVID-19 testing, and product approvals may hinder the growth of the COVID rapid diagnostic test market during the forecast period.
The market is segmented based on various factors, including type, end user, and region.
Segmentation by Type
Segmentation by End User
Hospitals and Clinics
Laboratories and Diagnostics Centers
Other End Users
Segmentation by Region
North America – United States, Canada, and Mexico
Europe – United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific – China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific
Latin America – Brazil, Argentina, and Rest of Latin America
Middle East and Africa – South Africa, GCC, and Rest of Middle East and Africa
The hospitals and clinics segment was the largest end user in the market studied. In terms of end users, the hospitals and clinics segment held the major share in the studied market with a value of USD 11,224.91 million in 2022. It is expected to witness a compound annual growth rate (CAGR) of -11.13% over the forecast period. Hospitals play a crucial role in healthcare systems as they are well-equipped with advanced kits, reagents, and instruments for diagnosing and monitoring infectious diseases. They are also the primary users of test kits for diagnosis. The growth of this segment is driven by an increase in the utilization of outpatient services and the affordability of care and diagnosis. Clinics, on the other hand, are smaller healthcare settings that offer primary healthcare services such as general checkups, sample collection, and routine tests.
In terms of test types, the antigen test segment had the largest share in the market studied. The antigen test segment held the major share in the studied market with a value of USD 12,575.06 million in 2022. It is expected to witness a CAGR of -10.76% over the forecast period. Antigen tests identify possible antigens, which are small proteins that make up the virus, in a patient’s sample. These tests provide a faster and less expensive way to diagnose active SARS-CoV-2 infection compared to nucleic acid amplification tests or molecular tests.
The molecular tests segment, which includes RT-PCR or nucleic acid amplification tests (NAATs), is expected to register a significant CAGR over the forecast period. Molecular tests amplify bits of viral RNA to detect viral infection through specialized testing. This segment primarily includes polymerase chain reaction (PCR) tests, loop-mediated isothermal amplification (LAMP), and clustered, regularly interspaced short palindromic repeat (CRISPR)-based assays. Molecular testing offers a higher level of selectivity and precision for COVID-19 diagnosis, making it the recommended gold standard by authorities such as the World Health Organization (WHO), European Union (EU), and the U.S. Food and Drug Administration (FDA). The market for molecular tests is positively impacted by the launch and approval of several innovative molecular diagnostic products. For example, miDiagnostics launched an ultrafast COVID-19 PCR test based on silicon chip technology, providing results in about 30 minutes. Sense Biodetection received CE Marking for Veros COVID-19, a fully integrated molecular diagnostic test that provides laboratory-quality results in 15 minutes.
The market for COVID rapid diagnostic tests exhibits a moderate level of fragmentation, with several prominent players operating within it. Noteworthy companies in this market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, bioMérieux SA, Quest Diagnostics Incorporated, and Danaher Corporation, among others.
Key Companies Profiled in this report include Abbott Laboratories, Thermo Fisher Scientific Inc., Cue Health Inc., Acon Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche Ltd, Siemens Healthcare AG, Quidel Corporation, bioMerieux SA, Quest Diagnostics Incorporated, PerkinElmer Inc., Creative Diagnostics, CTK Biotech, QIAGEN.
Recent Industry Developments
In January 2023, the Government of Canada granted approval for the Artron Laboratories COVID-19 Antigen Home Test, a rapid self-testing kit designed for detecting COVID antigens.
In January 2023, the Government of Canada also approved the Biomedomics Cov-scan Rapid Antigen Test for point-of-care testing purposes.
Key Questions Answered
What is the duration of the study period for this market?
What is the rate of growth for the COVID Rapid Diagnostic Test Market?
Which region exhibits the highest growth rate in the COVID Rapid Diagnostic Test Market?
Which region holds the largest share in the COVID Rapid Diagnostic Test Market?
Who are the major players in the COVID Rapid Diagnostic Test Market?